July 24 2012 Issue

1) Stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Atte Meretoja about her paper on reducing in-hospital delay. Dr. Jennifer Fugate is reading our e-Pearl of the week about mytonic dystrophy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Reisa Sperling about her plenary session on molecular and functional imaging detection of preclinical Alzheimer disease. The participants had nothing to disclose except Drs. Meretoja, Fugate, Espay and Sperling.Dr. Meretoja has served as a consultant for Boehringer Ingelheim, and has received honoraria from Boehringer Ingelheim for speaking at educational symposia, travel expenses from H Lundbeck A/S, and research support from Sigrid Juselius Foundation, Biomedicum Helsinki Foundation, Instrumentarium Science Foundation, Yrjo Jahnsson Foundation, Paivikki and Sakari Sohlberg Foundation, Maire Taponen Foundation, Finnish-Norwegian Medical Foundation and Emil Aaltonen Foundation.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Sperling received a speaker honorarium from Pfizer Inc.; serves on the editorial board of Alzheimer¹s disease and Associated Disorders; has served as a consultant for Roche, Janssen, Pfizer Inc, Bayer Schering Pharma, Eisai Inc., Satori, Kyowa Hakko Kirin, Bristol-Myers Squibb and Avid Radiopharmaceuticals, (unpaid); has received research support from Janssen, and Bristol-Myers Squibb, NIH/NIA, Alzheimer¹s Association, American Health Assistance Foundation, and an Anonymous Foundation.